FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914492017> ?p ?o ?g. }

• W2914492017 abstract "Purpose – to assess the impact of atorvastatin on plasma biomarkers and cardiovascular risk in patients with chronic lymphocytic leukemia in remission. Materials and methods. A total of 157 subjects with chronic lymphocytic leukemia in complete or partial remission were enrolled in the study. Atorvastatin at doses 20 mg/d and 40 mg/d were prescribed for patients with hypercholesterinemia, dyslipidemia and risk factors for coronary artery disease. Blood samples were collected for measurements of biomarkers such as galectin-3, VE-cadherin, VEGF-1, sCD40L, NT-proBNP and interleukin-6 by ELISA method at the time of inclusion into the study and after a 1-year follow-up. Cardiovascular events occurrence was assessed throughout a 3-year follow-up. Results. There were 170 clinical events occurred in 68 patients (43.3 %) within the follow-up, with the following distribution: 12 cardiovascular deaths, 17 life-threatening arrhythmias, 36 cardiac ischemic events, 9 strokes, 38 cases of chronic heart failure decompensation, and 58 hospital admissions for cardiovascular reasons. Patients were divided into two groups depending on the atorvastatin treatment. There were no differences in baseline levels of biomarkers between groups. Significant differences were observed in levels of galectin-3 (8.86 ± 5.62 ng/ml vs 16.74 ± 8.52 ng/ml; P = 0.035), VE-cadherin (0.76 ± 0.64 ng/ml vs 2.19 ± 1.66 ng/ml; P = 0.046) only in the group without atorvastatin treatment in the 1-year follow-up. Significant differences in levels of VEGF-1, IL-6, sCD40L, NT-proBNP were not revealed between groups during observation time. Atorvastatin treatment was associated with decreased cumulative cardiovascular event incidence with early differences in their occurrence between groups during the 3-year follow-up (log-rank test, χ 2 = 11.775, P = 0.001). Event-free survival were better in patients treated with atorvastatin 40 mg/d in comparison to patients treated with atorvastatin 20 mg/d (log-rank test, χ 2 = 6.147, P = 0.013) during the first year of follow-up. Conclusions. Among patients with chronic lymphocytic leukemia in remission, the key biomarkers of angiogenesis such as galectin-3 and VE-cadherin are associated with increased risk of cardiovascular events within 3-year follow up. Atorvastatin prevents an increase in angiogenesis biomarkers and reduces risk of cardiovascular events in this group of patients." @default.
• W2914492017 created "2019-02-21" @default.
• W2914492017 creator A5034389732 @default.
• W2914492017 date "2019-02-08" @default.
• W2914492017 modified "2023-10-18" @default.
• W2914492017 title "Influence of atorvastatin therapy on biological markers and cardiovascular risk in patients with chronic lymphocytic leukemia in remission" @default.
• W2914492017 cites W1993986769 @default.
• W2914492017 cites W2036699146 @default.
• W2914492017 cites W2037036977 @default.
• W2914492017 cites W2055040332 @default.
• W2914492017 cites W2068822247 @default.
• W2914492017 cites W2411113209 @default.
• W2914492017 cites W2527264311 @default.
• W2914492017 cites W2603584455 @default.
• W2914492017 cites W2765940080 @default.
• W2914492017 cites W2915478882 @default.
• W2914492017 cites W2982653531 @default.
• W2914492017 doi "https://doi.org/10.14739/2310-1210.2019.1.155793" @default.
• W2914492017 hasPublicationYear "2019" @default.
• W2914492017 type Work @default.
• W2914492017 sameAs 2914492017 @default.
• W2914492017 citedByCount "0" @default.
• W2914492017 crossrefType "journal-article" @default.
• W2914492017 hasAuthorship W2914492017A5034389732 @default.
• W2914492017 hasBestOaLocation W29144920171 @default.
• W2914492017 hasConcept C126322002 @default.
• W2914492017 hasConcept C164705383 @default.
• W2914492017 hasConcept C2777482532 @default.
• W2914492017 hasConcept C2777938653 @default.
• W2914492017 hasConcept C2778096610 @default.
• W2914492017 hasConcept C2778198053 @default.
• W2914492017 hasConcept C2778213512 @default.
• W2914492017 hasConcept C2778461978 @default.
• W2914492017 hasConcept C2779134260 @default.
• W2914492017 hasConcept C500558357 @default.
• W2914492017 hasConcept C71924100 @default.
• W2914492017 hasConcept C90924648 @default.
• W2914492017 hasConceptScore W2914492017C126322002 @default.
• W2914492017 hasConceptScore W2914492017C164705383 @default.
• W2914492017 hasConceptScore W2914492017C2777482532 @default.
• W2914492017 hasConceptScore W2914492017C2777938653 @default.
• W2914492017 hasConceptScore W2914492017C2778096610 @default.
• W2914492017 hasConceptScore W2914492017C2778198053 @default.
• W2914492017 hasConceptScore W2914492017C2778213512 @default.
• W2914492017 hasConceptScore W2914492017C2778461978 @default.
• W2914492017 hasConceptScore W2914492017C2779134260 @default.
• W2914492017 hasConceptScore W2914492017C500558357 @default.
• W2914492017 hasConceptScore W2914492017C71924100 @default.
• W2914492017 hasConceptScore W2914492017C90924648 @default.
• W2914492017 hasLocation W29144920171 @default.
• W2914492017 hasOpenAccess W2914492017 @default.
• W2914492017 hasPrimaryLocation W29144920171 @default.
• W2914492017 hasRelatedWork W1972656835 @default.
• W2914492017 hasRelatedWork W2003158566 @default.
• W2914492017 hasRelatedWork W2011278451 @default.
• W2914492017 hasRelatedWork W2051712573 @default.
• W2914492017 hasRelatedWork W2061508526 @default.
• W2914492017 hasRelatedWork W2107400784 @default.
• W2914492017 hasRelatedWork W2167244631 @default.
• W2914492017 hasRelatedWork W2328354663 @default.
• W2914492017 hasRelatedWork W2979861098 @default.
• W2914492017 hasRelatedWork W3141700921 @default.
• W2914492017 isParatext "false" @default.
• W2914492017 isRetracted "false" @default.
• W2914492017 magId "2914492017" @default.
• W2914492017 workType "article" @default.